Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
J Neuropsychiatry Clin Neurosci ; 20(4): 485-6, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19196935

RESUMO

There is very limited information available on the use of psychotropic drugs in consecutive pregnancies. The authors report a case of a woman with schizophrenia wherein risperidone was used successfully in two consecutive pregnancies. This is only the second known report in the existing literature in which atypical antipsychotic was used successfully in two successive pregnancies.


Assuntos
Antipsicóticos/uso terapêutico , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/psicologia , Risperidona/uso terapêutico , Esquizofrenia/tratamento farmacológico , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Resultado da Gravidez , Escalas de Graduação Psiquiátrica , Adulto Jovem
18.
Indian J Psychiatry ; 52(2): 187-90, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20838509

RESUMO

BACKGROUND: The Indian Journal of Psychiatry receives many reports which, despite obvious academic worth, are too poorly written to be publishable. Such submissions tax manuscript reviewers and increase the editorial office workload without benefiting the authors with a publication. METHODS: We describe an authentic and previously unpublished case of idiopathic leucopenia and psychosis. Leucocyte levels in this patient dropped upon challenge with different atypical antipsychotic drugs. Lithium pretreatment, however, permitted the safe and successful use of trifluperazine. Readers are invited to use a roughly-prepared version of the case report to draft a submission-worthy manuscript. RESULTS: Two versions of the manuscript are presented. The first version is generally satisfactory but will trigger several queries during peer review; these queries are indicated. The second version would be considered acceptable by most reviewers. CONCLUSIONS: Readers who work through the exercise provided in this article will better understand how authors should prepare their report and how reviewers may scrutinize their manuscript.

19.
World J Biol Psychiatry ; 10(4 Pt 2): 671-2, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19165653

RESUMO

Atomoxetine is the only FDA-approved non-stimulant to treat ADHD. We report a case of Atomoxetine-related exacerbation of nocturnal bruxism in a 12-yr old boy with ADHD, subsiding on discontinuing the drug, but re-worsening with retrial, finally subsiding upon adding Buspirone. This is the first report of its kind showing such an association, not included in any pre- or post-marketing data. Clinical implications and possible mechanisms are discussed.


Assuntos
Inibidores da Captação Adrenérgica/efeitos adversos , Bruxismo/induzido quimicamente , Propilaminas/efeitos adversos , Inibidores da Captação Adrenérgica/uso terapêutico , Sistemas de Notificação de Reações Adversas a Medicamentos , Cloridrato de Atomoxetina , Atenção/efeitos dos fármacos , Bruxismo/psicologia , Criança , Seguimentos , Humanos , Masculino , Propilaminas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa